Patients with high risk prostate cancer may benefit 'equally' from two new treatments
(European Society for Medical Oncology) Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | International Medicine & Public Health | Politics | Prostate Cancer